Physician profile
Mickey R Tyrrell
NPI 1710925680
$22,079.28
in general payments reported to CMS, 2019-2025
52 companies · $4,068 in 2025
The $4,068 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,023 · 2020: $2,105 · 2021: $3,079 · 2022: $3,273 · 2023: $3,676 · 2024: $3,854 · 2025: $4,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,341.28 |
| Education | $256.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,137.20 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Astrazeneca Pharmaceuticals LP | $2,016.04 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,555.71 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,472.46 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,461.18 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,407.10 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,327.44 | 2019-2025 | |
| Novo Nordisk INC | $1,269.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Alkermes, INC. | $845.89 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $780.15 | 2020-2025 | Rexulti |
| Lilly USA, LLC | $716.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $706.85 | 2019-2025 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.01 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $572.99 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $550.84 | 2019-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mickey Tyrrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.